Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ceroid-lipofuscinosis neuronal protein 5 (CLN5)
- Target
- CLN5
- Molecular classification
- Other (Lysosomal protein), Enzyme (cysteine palmitoyl thioesterase — S-depalmitoylase activity), Lysosomal membrane or soluble glycoprotein, Member of the N1pC/P60 superfamily of papain-like enzymes (by structural homology)
01
Overview
Ceroid-lipofuscinosis neuronal protein 5 (CLN5) is a lysosomal protein whose genetic mutations cause neuronal ceroid lipofuscinosis (NCL), a fatal recessive pediatric neurodegenerative disease. Structurally, CLN5 is a member of the N1pC/P60 superfamily with a unique cysteine-based active site acting as an S-depalmitoylase, crucial for removing palmitate modifications from lysosomal proteins—a modification essential for protein sorting and turnover. CLN5 contributes to endosome-lysosome trafficking, mitochondrial function, and neuronal protein/lipid homeostasis. Despite being essential for neuronal and lysosomal biology, CLN5 itself is not a direct therapeutic target, though its dysfunction elucidates key disease mechanisms in NCL and related lysosomal disorders.
- Other names
- CLN5Neuronal ceroid lipofuscinosis protein 5NCL protein 5
02
Mechanism of action
Not applicable; no specific drugs target this protein. Theoretically, in experimental systems, modulation of its palmitoyl thioesterase (S-depalmitoylation) activity could impact lysosomal function and neuronal viability.
03
Biological functions
Lysosomal homeostasis and substrate traffickingProtein S-depalmitoylation (thioesterase activity regulating protein lipid modifications)Regulation of endosomal-lysosomal sorting and retrograde trafficking (interaction with retromer and sorting receptors)Mitochondrial function and dynamics (ATP synthase c subunit interaction, network integrity, oxidative stress)Autophagy regulation
04
Disease associations
Neurodegenerative disease (neural ceroid lipofuscinosis/"Batten disease")—main known pathological associationAlzheimer's disease (possible contributor by variant association)Lysosomal storage disorder (group of NCLs)
05
Safety considerations
Loss-of-function in CLN5 causes severe, progressive neurodegeneration due to lysosomal dysfunction (inherited lysosomal storage disease). No exogenous pharmacological modulation safety data available.
06
Biomarkers
None in current clinical use.Mutations in CLN5 gene are used as a genetic diagnostic marker for late infantile NCL.
Beyond the preview
Go deeper on Ceroid-lipofuscinosis neuronal protein 5 (CLN5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ceroid-lipofuscinosis neuronal protein 5 (CLN5).